Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03799601 | Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC(ALTER-L013) | unknown | Phase 4 | 45 | Tongji HospitalOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03791151 | Pharmacogenetics in Non Small Cell Lung Cancer | unknown | — | 100 | Ain Shams UniversityOTHER | 1 | Jan 2, 2019 | clinicaltrials |
| NCT03565120 | Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer | unknown | N/A | 60 | yu gengshengOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT03432156 | Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 68 | Beijing Friendship HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03771404 | NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" | unknown | N/A | 50 | Hellenic Oncology Research GroupOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT03765775 | Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | unknown | Phase 2 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT03732001 | A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC(ALTER-L024) | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT03754530 | Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation | unknown | Phase 2 | 162 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT03750916 | Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer(ACDFNSNSCLC) | unknown | Phase 2 | 46 | Qilu Hospital of Shandong UniversityOTHER | 0 | Nov 26, 2018 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT03664843 | Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients | unknown | — | 120 | First Hospital of Shijiazhuang CityOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03735264 | Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）(ACDFNSCLC) | unknown | Phase 2 | 46 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Nov 8, 2018 | clinicaltrials |
| NCT03728374 | Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma | unknown | Phase 2 | 38 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Nov 2, 2018 | clinicaltrials |
| NCT03725423 | Apatinib for Advanced Lung Squmamous Carcinoma | unknown | Phase 4 | 50 | Xuzhou Central HospitalOTHER | 0 | Oct 31, 2018 | clinicaltrials |
| NCT01788332 | Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)(PIN) | unknown | Phase 2 | 70 | Lisette NixonOTHER_GOV | 1 | Oct 26, 2018 | clinicaltrials |
| NCT03710629 | A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes | unknown | — | 750 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT03700333 | Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC | unknown | Phase 3 | 120 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03692442 | Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform | unknown | — | 80 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03680183 | Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV) | unknown | — | 300 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT02811354 | Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA(PLASMA) | unknown | Phase 2 | 108 | National University Hospital, SingaporeOTHER | 5 | Sep 20, 2018 | clinicaltrials |
| NCT03671538 | Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin | unknown | N/A | 62 | Lingyu LuoOTHER | 0 | Sep 17, 2018 | clinicaltrials |
| NCT03672136 | Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients | unknown | Phase 2 | 25 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03407300 | A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 2 | 80 | Haining Health-Coming Biotech Co., Ltd.OTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01407822 | Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer(EMERGING) | unknown | Phase 2 / Phase 3 | 72 | Guangdong Association of Clinical TrialsOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT03108560 | Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer | unknown | N/A | 600 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT03509779 | Pronostic and Predictive Value of EMT in Localized Lung Cancer(TWISTlung) | unknown | — | 1,000 | European Georges Pompidou HospitalOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT01669707 | Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 60 | Beijing Chest HospitalOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT03656393 | To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma(RCTACSCNSCLC) | unknown | Phase 3 | 48 | Shenzhen People's HospitalOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT03654027 | Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC | unknown | Phase 2 | 84 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT02450656 | Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer(M14AFS) | unknown | Phase 1 / Phase 2 | 320 | The Netherlands Cancer InstituteOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT03480230 | Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | unknown | Phase 2 | 60 | Arafat TfayliOTHER | 2 | Aug 14, 2018 | clinicaltrials |
| NCT03616691 | Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC | unknown | Phase 2 | 46 | Samsung Medical CenterOTHER | 0 | Aug 6, 2018 | clinicaltrials |
| NCT03614065 | Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC | unknown | Phase 2 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 3, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT03602027 | Phase I Study of the Combination of Anlotinib With Gefitinib | unknown | N/A | 9 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT02507518 | Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer(CALMETTE) | unknown | Phase 2 | 80 | Centre Henri BecquerelOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT03594682 | Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study | unknown | N/A | 31 | Beijing Chest HospitalOTHER | 0 | Jul 20, 2018 | clinicaltrials |
| NCT03396185 | Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02433574 | Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection(LINNEARRE-I) | unknown | N/A | 20 | Juravinski Cancer CenterOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT03583723 | Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LARTIA Trial)(LARTIA) | unknown | N/A | 50 | Campus Bio-Medico UniversityOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT02980536 | cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | unknown | — | 129 | Berry Genomics Co., Ltd.INDUSTRY | 1 | Jul 11, 2018 | clinicaltrials |
| NCT02655536 | Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial(BRILLIANT) | unknown | Phase 2 | 109 | National Taiwan University HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT03533127 | A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer | unknown | Phase 3 | 648 | Luye Pharma Group Ltd.INDUSTRY | 1 | Jul 10, 2018 | clinicaltrials |
| NCT03566576 | Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel | unknown | N/A | 18 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 25, 2018 | clinicaltrials |
| NCT03546452 | A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC | unknown | — | 50 | Shanghai Chest HospitalOTHER | 1 | Jun 7, 2018 | clinicaltrials |
| NCT02956551 | Personalized DC Vaccine for Lung Cancer(SKLB1608) | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 31, 2018 | clinicaltrials |
| NCT03527251 | Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC(SEQUENCE) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT02696525 | Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients | unknown | — | 145 | Peking University People's HospitalOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT03525782 | Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC | unknown | Phase 1 / Phase 2 | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jan 10, 2019source: clinicaltrials